Phase and context shape the function of composite oncogenic mutations Journal Article


Authors: Gorelick, A. N.; Sánchez-Rivera, F. J.; Cai, Y.; Bielski, C. M.; Biederstedt, E.; Jonsson, P.; Richards, A. L.; Vasan, N.; Penson, A. V.; Friedman, N. D.; Ho, Y. J.; Baslan, T.; Bandlamudi, C.; Scaltriti, M.; Schultz, N.; Lowe, S. W.; Reznik, E.; Taylor, B. S.
Article Title: Phase and context shape the function of composite oncogenic mutations
Abstract: Cancers develop as a result of driver mutations1,2 that lead to clonal outgrowth and the evolution of disease3,4. The discovery and functional characterization of individual driver mutations are central aims of cancer research, and have elucidated myriad phenotypes5 and therapeutic vulnerabilities6. However, the serial genetic evolution of mutant cancer genes7,8 and the allelic context in which they arise is poorly understood in both common and rare cancer genes and tumour types. Here we find that nearly one in four human tumours contains a composite mutation of a cancer-associated gene, defined as two or more nonsynonymous somatic mutations in the same gene and tumour. Composite mutations are enriched in specific genes, have an elevated rate of use of less-common hotspot mutations acquired in a chronology driven in part by oncogenic fitness, and arise in an allelic configuration that reflects context-specific selective pressures. cis-acting composite mutations are hypermorphic in some genes in which dosage effects predominate (such as TERT), whereas they lead to selection of function in other genes (such as TP53). Collectively, composite mutations are driver alterations that arise from context- and allele-specific selective pressures that are dependent in part on gene and mutation function, and which lead to complex—often neomorphic—functions of biological and therapeutic importance. © 2020, The Author(s), under exclusive licence to Springer Nature Limited.
Keywords: controlled study; human tissue; gene mutation; major clinical study; promoter region; somatic mutation; missense mutation; mutation; nonhuman; prospective study; protein domain; mouse; phenotype; allele; animal tissue; melanoma; gene expression; tumor volume; animal experiment; protein binding; cohort analysis; genetic association; gene frequency; lung cancer; gene function; genetic transcription; prostate cancer; oncogene; tumor suppressor gene; binding site; tumor; site directed mutagenesis; genetic algorithm; disease; composite; pten gene; chronology; apc gene; tp53 gene; vulnerability; tert gene; cancer; human; female; priority journal; article; map3ca gene
Journal Title: Nature
Volume: 582
Issue: 7810
ISSN: 0028-0836
Publisher: Nature Publishing Group  
Date Published: 2020-06-04
Start Page: 100
End Page: 103
Language: English
DOI: 10.1038/s41586-020-2315-8
PUBMED: 32461694
PROVIDER: scopus
PMCID: PMC7294994
DOI/URL:
Notes: Article -- Export Date: 1 July 2020 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Scott W Lowe
    249 Lowe
  2. Barry Stephen Taylor
    238 Taylor
  3. Nikolaus D Schultz
    486 Schultz
  4. Maurizio Scaltriti
    169 Scaltriti
  5. Eduard Reznik
    103 Reznik
  6. Karl Philip Jonsson
    50 Jonsson
  7. Alexander Vincent Penson
    54 Penson
  8. Timour Baslan
    46 Baslan
  9. Craig Bielski
    23 Bielski
  10. Neil Vasan
    19 Vasan
  11. Yanyan Cai
    15 Cai
  12. Yu-jui Ho
    40 Ho